HD-OPM Archive
Topics › Brain health & dementia

Blood p-Tau 217 testing can flag Alzheimer's pathology years before symptoms

Louis Nervegna · Oct 28, 2026 · ♥ 6 reactions · 0 comments · original Facebook post
Brain health & dementiaRisk assessment & lab tests
AI summary & key facts

A shared promotional post argues that high-sensitivity p-Tau 217, alongside NfL and GFAP, can identify Alzheimer's-related pathology before symptoms and should be used for preventive follow-up. It describes Alzheimer's as a 20 to 40 year silent cascade. No specific study is cited.

We now have blood tests that can predict your risk for Alzheimer’s years before symptoms appear— when there is still time for prevention.

#ptau217HD #nflHD #gfapHD

Alzheimer’s is a slow, initially silent 20- to 40+-year pathophysiological cascade. Waiting for symptoms before evaluating your brain is like waiting for flames to burst through the roof before checking the smoke detector.

This is why high-sensitivity p-Tau 217 testing marks a monumental turning point in preventative and longitudinal follow-up medicine. P-Tau 217 can identify Alzheimer's-related pathology in pre-symptomatic and early symptomatic individuals. When evaluated alongside NfL (a marker of ongoing neuronal damage) and GFAP (a marker of astrocytic neuroinflammation and repair)—as we do in Apollo Health's BrainScan blood test—you get an accurate view of what is happening inside the brain, so just as we should all know our blood pressure and lipid profile, we should also know our p-Tau 217.

Comment ptau217, and I'll send you a link to learn more about p-Tau 217.

May be a graphic of text
← newer: EVITA: vitamin C cut deaths in early blood cancers, 11 vs 24older: Louis Ignarro on why nitric oxide won a Nobel Prize and its →